Kintiga

Kintiga is Europe's leading independent specialist pharmaceutical and biotechnology management consultancy, formed through the unification of three pioneering companies: MAP Patient Access, AxTalis, and SKC. The company specializes in providing comprehensive market access solutions that help health technology developers navigate the complex European regulatory and payer landscape to achieve successful patient access across Europe.

As a pan-European strategic consultancy, Kintiga operates at the intersection of strategy, evidence, and local expertise. The company offers tailored solutions encompassing pharmaceutical market access consultancy, regulatory strategy, medical affairs, and health economics and outcomes research (HEOR). Their clients span the full spectrum of healthcare innovation, including pharmaceutical companies, biotechnology firms, medtech developers, digital health companies, and diagnostic manufacturers. Kintiga is particularly focused on supporting the successful launch and reimbursement of breakthrough therapies and orphan drugs, as well as products setting new therapy standards. The company combines deep local market expertise with a global perspective to deliver impactful, innovative solutions that make a meaningful difference in patient access to life-changing treatments across Europe.